| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash (used in) / provided by investing activities | -14 | -2 |
| Repayment of exchangeable notes | 14,745 | 14,745 |
| Proceeds from issuance of ordinary shares, net of transaction costs | 16,909 | 11,477 |
| Net cash provided by financing activities | 2,164 | -3,268 |
| Effect of exchange rates on cash and cash equivalents | -20 | -18 |
| Net (decrease) / increase in cash, cash equivalents and restricted cash | -13,128 | -11,099 |
| Cash and cash equivalents at beginning of period | 24,159 | - |
| Cash and cash equivalents at end of period | 11,031 | - |
Iterum Therapeutics plc (ITRM)
Iterum Therapeutics plc (ITRM)